288 related articles for article (PubMed ID: 29672223)
1. Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.
Maurer MJ; Ghesquières H; Link BK; Jais JP; Habermann TM; Thompson CA; Haioun C; Allmer C; Johnston PB; Delarue R; Micallef IN; Peyrade F; Inwards DJ; Ketterer N; Farooq U; Fitoussi O; Macon WR; Molina TJ; Syrbu S; Feldman AL; Slager SL; Weiner GJ; Ansell SM; Cerhan JR; Salles GA; Witzig TE; Tilly H; Nowakowski GS
J Clin Oncol; 2018 Jun; 36(16):1603-1610. PubMed ID: 29672223
[TBL] [Abstract][Full Text] [Related]
2. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy.
Maurer MJ; Ghesquières H; Jais JP; Witzig TE; Haioun C; Thompson CA; Delarue R; Micallef IN; Peyrade F; Macon WR; Jo Molina T; Ketterer N; Syrbu SI; Fitoussi O; Kurtin PJ; Allmer C; Nicolas-Virelizier E; Slager SL; Habermann TM; Link BK; Salles G; Tilly H; Cerhan JR
J Clin Oncol; 2014 Apr; 32(10):1066-73. PubMed ID: 24550425
[TBL] [Abstract][Full Text] [Related]
3. Genome-Wide Association Study of Event-Free Survival in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Ghesquieres H; Slager SL; Jardin F; Veron AS; Asmann YW; Maurer MJ; Fest T; Habermann TM; Bene MC; Novak AJ; Mareschal S; Haioun C; Lamy T; Ansell SM; Tilly H; Witzig TE; Weiner GJ; Feldman AL; Dogan A; Cunningham JM; Olswold CL; Molina TJ; Link BK; Milpied N; Cox DG; Salles GA; Cerhan JR
J Clin Oncol; 2015 Nov; 33(33):3930-7. PubMed ID: 26460308
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma.
Maurer MJ; Micallef IN; Cerhan JR; Katzmann JA; Link BK; Colgan JP; Habermann TM; Inwards DJ; Markovic SN; Ansell SM; Porrata LF; Johnston PB; Nowakowski GS; Thompson CA; Gupta M; Syrbu SI; Kurtin PJ; Macon WR; Nikcevich DA; Witzig TE
J Clin Oncol; 2011 Apr; 29(12):1620-6. PubMed ID: 21383282
[TBL] [Abstract][Full Text] [Related]
5. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Maurer MJ; Jakobsen LH; Mwangi R; Schmitz N; Farooq U; Flowers CR; de Nully Brown P; Thompson CA; Frederiksen H; Cunningham D; Jørgensen J; Poeschel V; Nowakowski G; Seymour JF; Merli F; Haioun C; Ghesquieres H; Ziepert M; Tilly H; Salles G; Shi Q; El-Galaly TC; Habermann TM
Am J Hematol; 2021 May; 96(5):599-605. PubMed ID: 33661547
[TBL] [Abstract][Full Text] [Related]
6. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts.
Ghesquières H; Larrabee BR; Haioun C; Link BK; Verney A; Slager SL; Ketterer N; Ansell SM; Delarue R; Maurer MJ; Fitoussi O; Habermann TM; Peyrade F; Dogan A; Molina TJ; Novak AJ; Tilly H; Cerhan JR; Salles G
Hematol Oncol; 2017 Dec; 35(4):447-455. PubMed ID: 27282998
[TBL] [Abstract][Full Text] [Related]
7. Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma.
Thompson CA; Ghesquieres H; Maurer MJ; Cerhan JR; Biron P; Ansell SM; Chassagne-Clément C; Inwards DJ; Gargi T; Johnston PB; Nicolas-Virelizier E; Macon WR; Peix M; Micallef IN; Sebban C; Nowakowski GS; Porrata LF; Weiner GJ; Witzig TE; Habermann TM; Link BK
J Clin Oncol; 2014 Nov; 32(31):3506-12. PubMed ID: 25267745
[TBL] [Abstract][Full Text] [Related]
8. Personalized risk prediction for event-free survival at 24 months in patients with diffuse large B-cell lymphoma.
Maurer MJ; Jais JP; Ghesquières H; Witzig TE; Hong F; Haioun C; Thompson CA; Thieblemont C; Micallef IN; Porrata LF; Ribrag V; Nowakowski GS; Casasnovas O; Bologna S; Morschhauser F; Morrison VA; Peterson BA; Macon WR; Copie-Bergman C; Feldman AL; Syrbu SI; Kurtin PJ; Gascoyne RD; Li H; Allmer C; Kahl BS; Ansell SM; Slager SL; Link BK; Salles G; Habermann TM; Tilly H; Cerhan JR
Am J Hematol; 2016 Feb; 91(2):179-84. PubMed ID: 26492520
[TBL] [Abstract][Full Text] [Related]
9. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma.
Epperla N; Switchenko J; Bachanova V; Gerson JN; Barta SK; Gordon MJ; Danilov AV; Grover NS; Mathews S; Burkart M; Karmali R; Sawalha Y; Hill BT; Ghosh N; Park SI; Bond DA; Hamadani M; Fenske TS; Martin P; Malecek MK; Kahl BS; Flowers CR; Link BK; Kaplan LD; Inwards DJ; Feldman AL; Hsi ED; Maddocks K; Blum KA; Bartlett NL; Cerhan JR; Leonard JP; Habermann TM; Maurer MJ; Cohen JB
Blood Adv; 2023 Jun; 7(11):2287-2296. PubMed ID: 36516079
[TBL] [Abstract][Full Text] [Related]
10. Outcome of patients older than 80 years with diffuse large B-cell lymphoma (DLBCL) treated with "standard" immunochemotherapy: A large retrospective study from 4 institutions.
Gobba S; Moccia AA; Gulden-Sala W; Conconi A; Diem S; Cascione L; Iacoboni G; Margiotta-Casaluci G; Aprile von Hohenstaufen K; Stathis A; Hitz F; Pinotti G; Gaidano G; Zucca E
Hematol Oncol; 2018 Feb; 36(1):84-92. PubMed ID: 28621491
[TBL] [Abstract][Full Text] [Related]
11. Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell Lymphoma.
Alig S; Macaulay CW; Kurtz DM; Dührsen U; Hüttmann A; Schmitz C; Jin MC; Sworder BJ; Garofalo A; Shahrokh Esfahani M; Nabet BY; Soo J; Scherer F; Craig AFM; Casasnovas O; Westin JR; Gaidano G; Rossi D; Roschewski M; Wilson WH; Meignan M; Diehn M; Alizadeh AA
J Clin Oncol; 2021 Aug; 39(23):2605-2616. PubMed ID: 33909455
[TBL] [Abstract][Full Text] [Related]
12. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy.
Wang Y; Farooq U; Link BK; Larson MC; King RL; Maurer MJ; Allmer C; Hefazi M; Thompson CA; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Ansell SM; Cerhan JR; Nowakowski GS
J Clin Oncol; 2019 Jul; 37(21):1819-1827. PubMed ID: 31170029
[TBL] [Abstract][Full Text] [Related]
13. Hypercalcemia at diagnosis of diffuse large B-cell lymphoma is not uncommon and is associated with high-risk features and a short diagnosis-to-treatment interval.
Gauchy AC; Kanagaratnam L; Quinquenel A; Gaillard B; Rodier C; Godet S; Delmer A; Durot E
Hematol Oncol; 2020 Aug; 38(3):326-333. PubMed ID: 32270502
[TBL] [Abstract][Full Text] [Related]
14. Impact of Organ Function-Based Clinical Trial Eligibility Criteria in Patients With Diffuse Large B-Cell Lymphoma: Who Gets Left Behind?
Khurana A; Mwangi R; Nowakowski GS; Habermann TM; Ansell SM; LaPlant BR; Link BK; Cerhan JR; Maurer MJ; Witzig TE
J Clin Oncol; 2021 May; 39(15):1641-1649. PubMed ID: 33529046
[TBL] [Abstract][Full Text] [Related]
15. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients.
Prochazka KT; Melchardt T; Posch F; Schlick K; Deutsch A; Beham-Schmid C; Weiss L; Gary T; Neureiter D; Klieser E; Greil R; Neumeister P; Egle A; Pichler M
Br J Cancer; 2016 Nov; 115(10):1264-1272. PubMed ID: 27764838
[TBL] [Abstract][Full Text] [Related]
16. Shorter Diagnosis-to-Treatment Interval in Diffuse Large B-Cell Lymphoma is Associated With Inferior Overall Survival in a Large, Population-Based Registry.
Blunt DN; Smyth L; Nagamuthu C; Gatov E; Croxford R; Mozessohn L; Cheung MC
J Natl Compr Canc Netw; 2021 Mar; 19(6):719-725. PubMed ID: 33691276
[TBL] [Abstract][Full Text] [Related]
17. Early event status informs subsequent outcome in newly diagnosed follicular lymphoma.
Maurer MJ; Bachy E; Ghesquières H; Ansell SM; Nowakowski GS; Thompson CA; Inwards DJ; Allmer C; Chassagne-Clément C; Nicolas-Virelizier E; Sebban C; Lebras L; Sarkozy C; Macon WR; Feldman AL; Syrbu SI; Traverse-Glehan A; Coiffier B; Slager SL; Weiner GJ; Witzig TE; Habermann TM; Salles G; Cerhan JR; Link BK
Am J Hematol; 2016 Nov; 91(11):1096-1101. PubMed ID: 27465588
[TBL] [Abstract][Full Text] [Related]
18. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.
Xu PP; Fu D; Li JY; Hu JD; Wang X; Zhou JF; Yu H; Zhao X; Huang YH; Jiang L; Liu F; Su LP; Chen ZW; Zeng QS; Chen JP; Fang MY; Ma J; Liu T; Song YP; Yu K; Li Y; Qiu LG; Chen XQ; Gu J; Yan JS; Hou M; Huang HY; Wang L; Cheng S; Shen Y; Xiong H; Chen SJ; Zhao WL
Lancet Haematol; 2019 Jun; 6(6):e328-e337. PubMed ID: 31126528
[TBL] [Abstract][Full Text] [Related]
19. Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group.
Staiger AM; Ziepert M; Horn H; Scott DW; Barth TFE; Bernd HW; Feller AC; Klapper W; Szczepanowski M; Hummel M; Stein H; Lenze D; Hansmann ML; Hartmann S; Möller P; Cogliatti S; Lenz G; Trümper L; Löffler M; Schmitz N; Pfreundschuh M; Rosenwald A; Ott G;
J Clin Oncol; 2017 Aug; 35(22):2515-2526. PubMed ID: 28525305
[TBL] [Abstract][Full Text] [Related]
20. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
